Australia markets open in 8 hours 26 minutes

Bayer Aktiengesellschaft (BAYRY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.56-0.23 (-1.70%)
As of 11:18AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close13.80
Open13.60
Bid0.00 x 0
Ask0.00 x 0
Day's range13.55 - 13.68
52-week range12.45 - 18.45
Volume106,327
Avg. volume688,245
Market cap53.601B
Beta (5Y monthly)1.15
PE ratio (TTM)12.22
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.53 (3.85%)
Ex-dividend date02 May 2022
1y target estN/A
  • Zacks

    Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

    Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

  • Financial Times

    Bayer lifts forecasts as food shortages boost demand for seeds and weedkiller

    Bayer has upgraded its 2022 growth and profit forecasts, capitalising on the sharp rise in food prices that has boosted demand for seeds and weedkiller. The sharp increase in global food prices in the wake of Russia’s invasion of Ukraine has been a boon for Bayer’s crop sciences business, which accounts for half of its sales. While the unit booked a €1.3bn impairment charge linked to rising interest rates, its ebitda adjusted for one-offs surged 72 per cent to €1.75bn in the second quarter, while sales increased 29 per cent. Sales of herbicides alone rose 51 per cent.

  • Zacks

    Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent

    Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.